Friendswood, TX, United States of America

Zhisong Cao

This inventor holds 15 USPTO granted patents, plus 2 CIPO patents and 3 EPO patents. Top assignees: The Stehlin Foundation for Cancer Research, The Christus Stehlin Foundation for Cancer Research, Cao Pharmaceuticals Inc.. Active years: 1998-2017.

USPTO Granted Patents = 15

% Patents Active = 100.0

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 1.7

ph-index = 5

Forward Citations = 131(Granted Patents)

Company Filing History:

12 out of 24

The Stehlin Foundation for Cancer Research

patents

2 out of 2

The Christus Stehlin Foundation for Cancer Research

patents

1 out of 1

Cao Pharmaceuticals Inc.

patent

Years Active: 1998-2017

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9675609 - Nano- and micro-sized particles of 20-camptothecin or derivative thereof and pharmaceutical compositions containing same, and treatment of cancers therewith (2017-06-13),

2. 7928235 - Methods of making esters of camptothecins (2011-04-19),

3. 7572803 - Hydrated crystalline esters of camptothecin (2009-08-11),

4. 6703399 - Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds (2004-03-09),

5. 6699875 - Cascade esters of camptothecins and methods of treating cancer using these compounds (2004-03-02),

6. 6407239 - Aromatic esters of camptothecins and methods to treat cancers (2002-06-18),

7. 6407118 - Derivatives of camptothecin and methods of treating cancer using these derivatives (2002-06-18),

8. 6352996 - Liposomal prodrugs comprising derivatives of camptothecin and methods of treating cancer using these prodrugs (2002-03-05),

9. 6228855 - Aromatic esters of camptothecins and methods to treat cancers (2001-05-08),

10. 6218399 - Derivatives of camptothecin and methods of treating cancer using these derivatives (2001-04-17),

11. 6120793 - Methods of treating cancer using these derivatives (2000-09-19),

12. 6096336 - Liposomal prodrugs comprising derivatives of camptothecin and methods of (2000-08-01),

13. 5968943 - Derivatives of camptothecin and methods of treating cancer using these (1999-10-19),

14. 5922877 - Methods of preparing and purifying 9-nitro-20-camptothecin (1999-07-13),

15. 5731316 - Derivatives of camptothecin and methods of treating cancer using these (1998-03-24),

Title: Zhisong Cao: Innovator in Pharmaceutical Compositions

Introduction

Zhisong Cao is a prominent inventor based in Friendswood, TX (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative cancer treatments. With a total of 15 patents to his name, Cao's work focuses on enhancing the bioavailability and effectiveness of cancer medications.

Latest Patents

Cao's latest patents include groundbreaking work on nano- and micro-sized particles of 20-camptothecin or its derivatives. These pharmaceutical compositions are designed to improve the delivery and efficacy of cancer treatments. The particles are characterized by a mean size of less than about 2500 nm, allowing for better solubility and dispersibility in water. This innovation enables the active compound to be administered in a more bioavailable form, which can be utilized in oral pharmaceutical compositions such as aqueous suspensions, capsules, or caplets. Additionally, he has developed methods for preparing esters of camptothecins, which involve specific esterification and acylation reactions.

Career Highlights

Throughout his career, Zhisong Cao has worked with notable organizations, including the Stehlin Foundation for Cancer Research and the Christus Stehlin Foundation for Cancer Research. His research has significantly impacted the field of oncology, providing new avenues for effective cancer treatment.

Collaborations

Cao has collaborated with various professionals in the field, including Beppino C Giovanella, enhancing the scope and impact of his research.

Conclusion

Zhisong Cao's innovative work in pharmaceutical compositions showcases his dedication to improving cancer treatment options. His contributions continue to pave the way for advancements in the medical field, ultimately benefiting patients in need of effective therapies.